Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 935-783-6 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- GLP compliant OECD guideline 414 study, tested with the source substance CAS 59-50-7. According to the ECHA guidance document “Practical guide 6: How to report read-across and categories (March 2010)”, the reliability was changed from RL1 to RL2 to reflect the fact that this study was conducted on a read-across substance.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
- Report date:
- 1991
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OTS 798.4900 (Prenatal Developmental Toxicity Study)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Chlorocresol
- EC Number:
- 200-431-6
- EC Name:
- Chlorocresol
- Cas Number:
- 59-50-7
- Molecular formula:
- C7H7ClO
- IUPAC Name:
- 4-chloro-3-methylphenol
- Details on test material:
- - Name of test material (as cited in study report): Preventol CMK
- Physical state: Solid, colourless powder
- Analytical purity: 100%
- Lot/batch No.: 791
- Stability under test conditions: Was approved by the study sponsor.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Wistar (Bor:WISW(SPF Cpb))
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: F. Winkelmann, Borchen, Germany
- Age at study initiation: no data
- Weight at study initiation: 186 - 248 g
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5% aqueous tylose solution
- Details on exposure:
- VEHICLE
- Concentration in vehicle: 3.0, 10.0, 30.0 mg/mL
- Amount of vehicle: 10 mL/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on mating procedure:
- Virgin female rats were mated overnight individually with males. Females revealing vaginal plugs or spermatozoa in vaginal smears in the following morning were designated as being in day 0 of gestation.
- Duration of treatment / exposure:
- from day 6 to day 15 of gestation
- Frequency of treatment:
- daily
- Duration of test:
- 20 days (On day 20 of gestation animals delivered by caesarean section)
Doses / concentrations
- Remarks:
- Doses / Concentrations:
30, 100, 300 mg/kg bw/d
Basis:
actual ingested
- No. of animals per sex per dose:
- 25
- Control animals:
- yes, concurrent no treatment
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
From day 0 to 20 of gestation: twice daily (once on weekends and bank holidays)
BODY WEIGHT: Yes
Day 0 p.c.; Days 6 to 15 p.c.: once daily; day 20 p.c.
FOOD CONSUMPTION: Yes
Days of gestation: 0-6, 6-11, 11-16 and 16-20
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organ examined: Uterus weight
OTHER: Water consumption assessment was performed during inspections by visual inspection of the quantities left over. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Other: Individual weights and outward appearance of placentas - Fetal examinations:
- Examination of the fetuses included:
Determination of sex, weight, occurrence of malformations discernable from the outside and other findings deviating from standard, occurrence of visceral malformations (investigations of half of the foetuses according to the modified WILSON technique, occurrence of changes in the abdominal and thoracic organs and skeletal system (evisceration and evaluation of the other foetuses according to the DAWSON technique) - Indices:
- Sex ratio (m:f)
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:yes. Remark: at 300 mg/kg bw/d
Details on maternal toxic effects:
No treatment related effects were seen in animals of the 0 and 30 mg/kg bw/d dose group.
CLINICAL SIGNS:
100 mg/kg bw/d: on days 8 and 16 two animals showed laboured breathing
300 mg/kg bw/d: from day 8 post coitum (p.c.). marked clinical signs (rough coat, sunken flanks, bloody muzzle, laboured breathing, reduced mobility, high-stepping gait) were noted. From day 6 p.c. the following signs occurred from about 10 minutes until 1 hour after application: lying on side, somnolence, abdominal position, spastic convulsion. In addition, one animal showed gasped breathing.
MORTALITY:
0 - 100 mg/kg bw/d: no mortalities occurred
300 mg/kg bw/d: Six animals died during the study period, one of them was sacrificed in moribund condition.
FOOD INTAKE:
100 mg/kg bw/d: statistically significant reduced food intake during the application period.
300 mg/kg bw/d: statistically significant reduced food intake during the application and gestation period.
WATER INTAKE:
100 mg/kg bw/d: reduced in one animal on day 9 p.c.
300 mg/kg bw/d: reduced for several animals from day 9 p.c., in some cases lasting for 1-6 days.
URINE/FAECES EXCRETION:
100 mg/kg bw/d: increased urine excretion in some isolated cases from day 9 p.c.; reduced amount of faeces over a period of 1-5 days in several animals from day 9 p.c.
300 mg/kg bw/d: increased urine excretion in several animals from day 8 p.c. for a period of 1-5 days; reduced amount of faeces in several animals from day 8 p.c. (lasting for 1-5 days).
BODY WEIGHT:
100, 300 mg/kg bw/d: body weight gain was reduced during the treatment period. Body weight development during pregnancy as well as corrected body weight gain was statistically significant reduced.
GROSS PATHOLOGY:
0 - 100 mg/kg bw/d: no effects
300 mg/kg bw/d: Of the 6 animals that died or were sacrificed moribund during the study period, 2 and 3 animals had inflated intestines and bloody vaginas, respectively. Additional significant findings were noted in these animals. No findings were observed in the surviving animals of this dose group. For further details see Table 1 under: "Any other information on results".
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- LOAEL
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- NOAEL
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- LOAEL
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
- Dose descriptor:
- NOAEL
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:yes. Remark: at 300 mg/kg bw/d
Details on embryotoxic / teratogenic effects:
EMBRYOTOXICITY:
0 - 100 mg/kg bw/d: No effects
300 mg/kg bw/d: Reduced foetal weight. Due to an increased rate of resorption, the gestation rate and number of foetuses were also reduced.
TERATOGENICITY: No effects.
For further details see Table 2 under: "Any other information on results".
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Any other information on results incl. tables
Table 1: Overview of maternal effects in the prenatal developmental toxicity study
Parameter |
Control data |
30 mg/kg bw/d |
100 mg/kg bw/d |
300 mg/kg bw/d |
Dose-response |
|
historical |
0 mg/kg bw/d |
|||||
Number of dams examined |
- |
25 |
25 |
25 |
25 |
|
Clinical signs of toxicity |
||||||
audible breathing sounds |
- |
0 |
0 |
1 |
4 |
+ |
gasping breathing |
- |
0 |
0 |
1 |
1 |
+ |
bloody lip |
- |
0 |
1 |
0 |
0 |
- |
rough coat |
3 |
0 |
0 |
0 |
7 |
+ |
bloody muzzle |
1 (nose) |
0 |
0 |
0 |
4 |
+ |
sunken flanks |
1 |
0 |
0 |
0 |
3 |
+ |
reduced motility |
- |
0 |
0 |
0 |
2 |
+ |
abdominal knots |
- |
0 |
1 |
0 |
0 |
− |
bloody forelimbs |
- |
0 |
0 |
0 |
1 |
− |
high-stepping gait |
- |
0 |
0 |
0 |
1 |
+ |
reduced water intake |
7# |
0 |
0 |
1 |
12 |
+ |
light-brown, hard faeces |
4 |
1 |
0 |
0 |
0 |
|
small amount of faeces |
4 |
0 |
0 |
4 |
14 |
+ |
increased urine excretion |
5# |
0 |
0 |
3 |
9 |
+ |
after application |
|
|
|
|
|
|
gasping breathing |
- |
0 |
0 |
0 |
1 |
+ |
lying on side |
- |
0 |
0 |
0 |
7 |
+ |
somnolence |
- |
0 |
0 |
0 |
13 |
+ |
abdominal position |
- |
0 |
0 |
0 |
9 |
+ |
spastic convulsion |
- |
0 |
0 |
0 |
5 |
+ |
Mortality of dams |
- |
0 |
0 |
0 |
6 |
+ |
Body weight gain [g] Mean day 0 – 20 |
73.0 - 101.9 |
98.5 |
95.8 |
90.9 |
66.8* |
+ |
Body weight gain [g] corrected, day 0 – 20 |
- |
37.6 |
35.3 |
31.0 |
13.7*** |
+ |
Mean food consumption |
- |
18.5 |
18.4 |
18.0 |
15.5*** |
+ |
Pregnancies |
7-24 |
22 |
24 |
22 |
24 |
- |
Necropsy findings in dams dead before end of test |
||||||
reddened oesophagus |
- |
0 |
0 |
0 |
1 |
+ |
suppurative foci in lung tissue |
- |
0 |
0 |
0 |
1 |
+ |
fluid in thorax |
- |
0 |
0 |
0 |
1 |
+ |
thorax filled with serous fluid |
- |
0 |
0 |
0 |
1 |
+ |
stomach appears smaller |
- |
0 |
0 |
0 |
1 |
+ |
stomach + intestines extremely distended |
- |
0 |
0 |
0 |
1 |
+ |
reduced spleen size |
- |
0 |
0 |
0 |
1 |
+ |
gas-inflated intestines |
- |
0 |
0 |
0 |
2 |
+ |
bloody vagina |
1 |
0 |
0 |
0 |
3 |
+ |
organs autolytic |
- |
0 |
0 |
0 |
1 |
+ |
Necropsy findings in dams at termination |
||||||
Ovariary cysts |
1 |
2 |
0 |
0 |
0 |
− |
intestinal worms |
56 |
3 |
8 |
7 |
6 |
- |
# Skeletal retardations |
Table 2: Overview of developmental effects in the prenatal developmental toxicity study
Parameter |
Controldata |
30 mg/kg bw/d |
100 mg/kg bw/d |
300 mg/kg bw/d |
Dose-response |
|
Historical |
0 mg/kg bw/d |
|||||
Corpora lutea[mean no./dam] |
- |
13.0 |
13.2 |
12.4 |
12.6 |
|
Implantations[mean no./dam] |
8.3 - 12.5 |
11.4 |
11.3 |
11.2 |
10.6 |
– |
Resorptions[mean no./dam]a |
0.3 - 2.3 |
0.6 |
0.8 |
0.6 |
1.8*** |
+ |
Resorptions[mean no./dam]b |
0.6 |
0.8 |
0.6 |
0.7 |
- |
|
Foetuses[mean no./dam] |
7.6 - 11.7 |
10.7 |
10.5 |
10.6 |
9.9 |
– |
Foetus weight(mean) [g]b |
3.17 - 3.68 |
3.71 |
3.69 |
3.65 |
3.42** |
+ |
Placenta weight[mean/dam] [g]b |
0.55 - 0.68 |
0.62 |
0.65 |
0.62 |
0.60 |
– |
Skeletal changes |
1.44 - 3.18# |
2.09 |
1.46 |
2.18 |
1.38 |
− |
Malformations |
0.00 - 0.39 |
0.14 |
0.08 |
0.05 |
0.38 |
− |
Sex ratio (m:f)b |
- |
1:0.8 |
1:0.9 |
1:1.22 |
1:1.03 |
- |
awith implantations |
Applicant's summary and conclusion
- Conclusions:
- The test substance had no effect on intrauterine development at doses causing no maternal toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.